Frank Bernier on Nature Aging Breakthrough: Urolithin A Just Scored a Big Win for Immune Aging
Frank Bernier, R&D Unit Leader at GLICO, posted on LinkedIn:
”Urolithin A just scored a big win for immune aging.
A new randomized, double-blind, placebo-controlled trial in Nature Aging asked a simple question: if we improve mitochondrial quality, can we make aging immune cells act young again?
Healthy middle-aged adults took Urolithin A (1,000 mg/day) for 4 weeks. The results:
• ↑ Naive-like CD8⁺ T cells
• ↓ Terminally exhausted CD8⁺ T cells
• ↑ Fatty acid oxidation capacity in CD8⁺ T cells
• ↑ Mitochondrial biogenesis in immune cells
• ↑ NK cells and nonclassical monocytes
• Better functional responses (TNF secretion, bacterial uptake)
In other words: tuning mitophagy and mitochondria did not just support immunity in theory. It shifted real human immune cell phenotypes toward a more resilient, “younger” state in weeks.
Longevity is not only about adding years. It is about preserving immune memory, surveillance, and metabolic fitness so the system can still recognise, respond, and repair.
For anyone working in nutrition, microbiome, or healthy aging, this is a strong signal: mitochondria are not a side character. They are a primary target.
Article (Open Access) here.”
Title: Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial
Authors: Dominic Denk, Anurag Singh, Herbert G. Kasler, Davide D’Amico, Julia Rey, Lucía Alcober-Boquet, Johanna M. Gorol, Christoph Steup, Ritesh Tiwari, Ryan Kwok, Rafael J. Argüello, Julie Faitg, Kathrin Sprinzl, Stefan Zeuzem, Valentina Nekljudova, Sibylle Loibl, Eric Verdin, Chris Rinsch, Florian R. Greten
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A
-
Oct 16, 2026, 12:40Edward Lee Carter: How Factor XI Inhibition Could Transform Anticoagulation Therapy
-
Oct 16, 2026, 12:40Marc Carrier: Looking Ahead to ISTH 2027 in Vancouver
-
Oct 16, 2026, 12:30Bob Lempke: How One Blood Donation Can Save Up to Three Lives
-
Oct 16, 2026, 12:30Why VWF Therapies Belong on the EU Critical Medicines List – EHC
-
Oct 16, 2026, 12:17Exploring Endothelial Cells, Genetic Fate Mapping, and Revascularization – ISTH